Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables SH SC JW 2.8K 8th Aug, 2025
Maintain Buy with lower TP of IDR3,700
MYOR’s new growth engine
MYOR has consistently innovated to expand its market share domestically and abroad. Domestically, MYOR's wafer category grew from a 7% market share in 2018 to 24% in 2024, becoming a key growth driver. For FY25F and beyond, we expect new product categories – soft cakes (Bonita), savory snacks (Apetito), and soft candies (Fruta Gummy) – will drive future growth. The estimated market sizes in Indonesia for these categories are IDR8tn, IDR20tn, and IDR6tn, respectively, according to management. If these brands can achieve 30% market share, they could increase MYOR's domestic sales by >50%. With a competitive price point at a threshold of ~IDR 2,000 per piece, these new products are well-positioned to gain market share, especially amid weakening buying power condition, in our view. In the export market, MYOR continues to gain traction, particularly in the Philippines with new soluble coffee products and in Malaysia due to effective marketing. All in all, we believe MYOR has tremendous market share opportunities in both domestic and export markets.
Margin will gradually expand in 3Q25F onwards
MYOR continues to average down its raw material costs, especially for coffee and cocoa. We note that the price of Indonesia local coffee tends to decline much faster than that of global coffee due to increasing competition from coffee from Brazil, which has aggressively supplied to China. With weaker export shipments, this creates more coffee supply that is available in Indonesia. Cocoa prices have also dropped globally, as demand has weakened at the same time as palm kernel has acted as a substitute. All in all, we expect a slight recovery in 3Q25F with a notable margin recovery more apparent in 4Q25F.
Maintain Buy; all the bad news already priced in
We revise down FY25F-27F EPS by 2-7% due to higher-than-expected input costs, especially from more expensive coconut oil. That said, MYOR’s market share and sales keep expanding; hence, any improvement in margin will boost earnings significantly, in our view. Fundamentally, we see low downside risks currently. We maintain our Buy rating with lower TP of IDR3,700 (vs IDR4,000 previously), using an unchanged FY25F P/E of 26.5x. With implied upside of 67.4% and potential dividend yield of 3.5%, MYOR’s TSR is at 70.9%. Currently, the stock trades at a FY25F P/E of 16x. A downside risks is a tougher-than-expected competitive landscape.
| Year-end 31 Dec | FY24 | FY25F | FY26F | FY27F | |||
| Currency (IDR) | Actual | Old | New | Old | New | Old | New |
| Revenue (bn) | 36,073 | 40,871 | 40,871 | 45,857 | 45,857 | 51,451 | 51,451 |
| Reported net profit (bn) | 3,000 | 3,354 | 3,098 | 4,178 | 4,091 | 5,120 | 5,024 |
| Normalised net profit (bn) | 3,000 | 3,354 | 3,098 | 4,178 | 4,091 | 5,120 | 5,024 |
| FD normalised EPS | 134.19 | 150.01 | 138.54 | 186.86 | 182.96 | 229.00 | 224.68 |
| FD norm. EPS growth (%) | -6.1 | 11.8 | 3.2 | 24.6 | 32.1 | 22.6 | 22.8 |
| FD normalised P/E (x) | 16.5 | – | 16.0 | – | 12.1 | – | 9.8 |
| EV/EBITDA (x) | 10.9 | – | 10.2 | – | 8.0 | – | 6.7 |
| Price/book (x) | 2.9 | – | 2.8 | – | 2.4 | – | 2.1 |
| Dividend yield (%) | 3.4 | – | 3.5 | – | 4.6 | – | 5.7 |
| ROE (%) | 18.8 | 19.2 | 17.8 | 21.6 | 21.4 | 23.3 | 23.1 |
| Net debt/equity (%) | 19.9 | 12.1 | 13.8 | 6.0 | 7.1 | 3.1 | 4.3 |
Income statement (IDRbn) | |||||||||||||||||||
Year-end 31 Dec | FY23 | FY24 | FY25F | FY26F | FY27F | ||||||||||||||
Revenue | 31,485 | 36,073 | 40,871 | 45,857 | 51,451 | ||||||||||||||
Cost of goods sold | -23,077 | -27,771 | -31,656 | -34,828 | -38,595 | ||||||||||||||
Gross profit | 8,408 | 8,302 | 9,214 | 11,028 | 12,856 | ||||||||||||||
SG&A | -4,108 | -4,387 | -5,109 | -5,732 | -6,431 | ||||||||||||||
Employee share expense | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Operating profit | 4,299 | 3,915 | 4,105 | 5,296 | 6,425 | ||||||||||||||
EBITDA | 5,130 | 4,883 | 5,131 | 6,384 | 7,578 | ||||||||||||||
Depreciation | -831 | -968 | -1,026 | -1,087 | -1,153 | ||||||||||||||
Amortisation | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
EBIT | 4,299 | 3,915 | 4,105 | 5,296 | 6,425 | ||||||||||||||
Net interest expense | -218 | -274 | -185 | -112 | -53 | ||||||||||||||
Associates & JCEs | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other income | 12 | 240 | 92 | 93 | 94 | ||||||||||||||
Earnings before tax | 4,094 | 3,881 | 4,013 | 5,278 | 6,466 | ||||||||||||||
Income tax | -849 | -813 | -843 | -1,108 | -1,358 | ||||||||||||||
Net profit after tax | 3,245 | 3,068 | 3,170 | 4,169 | 5,108 | ||||||||||||||
Minority interests | -51 | -67 | -73 | -78 | -85 | ||||||||||||||
Other items | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Preferred dividends | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Normalised NPAT | 3,194 | 3,000 | 3,098 | 4,091 | 5,024 | ||||||||||||||
Extraordinary items | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Reported NPAT | 3,194 | 3,000 | 3,098 | 4,091 | 5,024 | ||||||||||||||
Dividends | -1,622 | -1,687 | -1,744 | -2,293 | -2,810 | ||||||||||||||
Transfer to reserves | 1,571 | 1,313 | 1,354 | 1,798 | 2,214 | ||||||||||||||
Valuations and ratios | |||||||||||||||||||
Reported P/E (x) | 15.5 | 16.5 | 16.0 | 12.1 | 9.8 | ||||||||||||||
Normalised P/E (x) | 15.5 | 16.5 | 16.0 | 12.1 | 9.8 | ||||||||||||||
FD normalised P/E (x) | 15.5 | 16.5 | 16.0 | 12.1 | 9.8 | ||||||||||||||
Dividend yield (%) | 3.3 | 3.4 | 3.5 | 4.6 | 5.7 | ||||||||||||||
Price/cashflow (x) | 9.4 | – | 10.3 | 10.5 | – | ||||||||||||||
Price/book (x) | 3.3 | 2.9 | 2.8 | 2.4 | 2.1 | ||||||||||||||
EV/EBITDA (x) | 9.7 | 10.9 | 10.2 | 8.0 | 6.7 | ||||||||||||||
EV/EBIT (x) | 11.6 | 13.5 | 12.7 | 9.7 | 7.9 | ||||||||||||||
Gross margin (%) | 26.7 | 23.0 | 22.5 | 24.0 | 25.0 | ||||||||||||||
EBITDA margin (%) | 16.3 | 13.5 | 12.6 | 13.9 | 14.7 | ||||||||||||||
EBIT margin (%) | 13.7 | 10.9 | 10.0 | 11.5 | 12.5 | ||||||||||||||
Net margin (%) | 10.1 | 8.3 | 7.6 | 8.9 | 9.8 | ||||||||||||||
Effective tax rate (%) | 20.7 | 21.0 | 21.0 | 21.0 | 21.0 | ||||||||||||||
Dividend payout (%) | 50.8 | 56.2 | 56.3 | 56.1 | 55.9 | ||||||||||||||
ROE (%) | 23.1 | 18.8 | 17.8 | 21.4 | 23.1 | ||||||||||||||
ROA (pretax %) | 22.2 | 17.5 | 16.2 | 20.1 | 22.5 | ||||||||||||||
Growth (%) | |||||||||||||||||||
Revenue | 2.7 | 14.6 | 13.3 | 12.2 | 12.2 | ||||||||||||||
EBITDA | 56.4 | -4.8 | 5.1 | 24.4 | 18.7 | ||||||||||||||
Normalised EPS | 64.4 | -6.1 | 3.2 | 32.1 | 22.8 | ||||||||||||||
Normalised FDEPS | 64.4 | -6.1 | 3.2 | 32.1 | 22.8 | ||||||||||||||
Source: Company data, Verdhana estimates | |||||||||||||||||||
Cashflow statement (IDRbn) | |||||||||||||||||||
Year-end 31 Dec | FY23 | FY24 | FY25F | FY26F | FY27F | ||||||||||||||
EBITDA | 5,130 | 4,883 | 5,131 | 6,384 | 7,578 | ||||||||||||||
Change in working capital | 1,129 | -4,143 | 674 | -468 | -1,441 | ||||||||||||||
Other operating cashflow | -1,030 | -915 | -1,008 | -1,206 | -7,578 | ||||||||||||||
Cashflow from operations | 5,230 | -175 | 4,797 | 4,710 | -1,441 | ||||||||||||||
Capital expenditure | -2,346 | -2,306 | -1,968 | -2,026 | -935 | ||||||||||||||
Free cashflow | 2,883 | -2,481 | 2,829 | 2,685 | -2,376 | ||||||||||||||
Reduction in investments | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Net acquisitions | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Dec in other LT assets | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Inc in other LT liabilities | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Adjustments | -113 | 342 | -3 | -3 | -3 | ||||||||||||||
CF after investing acts | 2,771 | -2,139 | 2,826 | 2,681 | -2,379 | ||||||||||||||
Cash dividends | -797 | -1,622 | -1,687 | -1,744 | -2,293 | ||||||||||||||
Equity issue | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Debt issue | -1,130 | 3,764 | -990 | -731 | -546 | ||||||||||||||
Convertible debt issue | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Others | 51 | 442 | -273 | 93 | 5,124 | ||||||||||||||
CF from financial acts | -1,876 | 2,584 | -2,950 | -2,381 | 2,284 | ||||||||||||||
Net cashflow | 895 | 445 | -124 | 300 | -94 | ||||||||||||||
Beginning cash | 3,262 | 4,157 | 4,601 | 4,478 | 4,778 | ||||||||||||||
Ending cash | 4,157 | 4,601 | 4,478 | 4,778 | 4,683 | ||||||||||||||
Ending net debt | 106 | 3,347 | 2,480 | 1,449 | 997 | ||||||||||||||
Balance sheet (IDRbn) | |||||||||||||||||||
As at 31 Dec | FY23 | FY24 | FY25F | FY26F | FY27F | ||||||||||||||
Cash & equivalents | 4,157 | 4,601 | 4,478 | 4,778 | 4,683 | ||||||||||||||
Marketable securities | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Accounts receivable | 6,197 | 7,252 | 7,640 | 8,166 | 9,163 | ||||||||||||||
Inventories | 3,557 | 6,437 | 5,637 | 5,725 | 6,344 | ||||||||||||||
Other current assets | 828 | 1,310 | 1,120 | 1,256 | 1,410 | ||||||||||||||
Total current assets | 14,739 | 19,601 | 18,875 | 19,925 | 21,600 | ||||||||||||||
LT investments | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Fixed assets | 8,160 | 9,498 | 10,440 | 11,378 | 12,313 | ||||||||||||||
Goodwill | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other intangible assets | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other LT assets | 972 | 630 | 633 | 636 | 639 | ||||||||||||||
Total assets | 23,870 | 29,729 | 29,948 | 31,940 | 34,552 | ||||||||||||||
Short-term debt | 729 | 3,825 | 3,041 | 2,506 | 2,146 | ||||||||||||||
Accounts payable | 1,895 | 2,441 | 2,264 | 2,395 | 2,548 | ||||||||||||||
Other current liabilities | 1,389 | 1,117 | 1,366 | 1,517 | 1,692 | ||||||||||||||
Total current liabilities | 4,013 | 7,383 | 6,670 | 6,418 | 6,386 | ||||||||||||||
Long-term debt | 3,533 | 4,123 | 3,917 | 3,721 | 3,535 | ||||||||||||||
Convertible debt | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other LT liabilities | 1,042 | 1,120 | 1,120 | 1,120 | 1,120 | ||||||||||||||
Total liabilities | 8,588 | 12,626 | 11,707 | 11,259 | 11,041 | ||||||||||||||
Minority interest | 243 | 282 | 296 | 311 | 326 | ||||||||||||||
Preferred stock | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Common stock | 447 | 447 | 447 | 447 | 447 | ||||||||||||||
Retained earnings | 14,605 | 16,384 | 17,497 | 19,922 | 22,738 | ||||||||||||||
Proposed dividends | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other equity and reserves | -13 | -11 | 0 | 0 | 0 | ||||||||||||||
Total shareholders' equity | 15,039 | 16,820 | 17,944 | 20,370 | 23,185 | ||||||||||||||
Total equity & liabilities | 23,870 | 29,728 | 29,947 | 31,940 | 34,552 | ||||||||||||||
Liquidity (x) | |||||||||||||||||||
Current ratio | 3.67 | 2.65 | 2.83 | 3.10 | 3.38 | ||||||||||||||
Interest cover | 19.7 | 14.3 | 22.2 | 47.3 | 122.1 | ||||||||||||||
Leverage | |||||||||||||||||||
Net debt/EBITDA (x) | 0.02 | 0.69 | 0.48 | 0.23 | 0.13 | ||||||||||||||
Net debt/equity (%) | 0.7 | 19.9 | 13.8 | 7.1 | 4.3 | ||||||||||||||
Per share | |||||||||||||||||||
Reported EPS (IDR) | 142.84 | 134.19 | 138.54 | 182.96 | 224.68 | ||||||||||||||
Norm EPS (IDR) | 142.84 | 134.19 | 138.54 | 182.96 | 224.68 | ||||||||||||||
FD norm EPS (IDR) | 142.84 | 134.19 | 138.54 | 182.96 | 224.68 | ||||||||||||||
BVPS (IDR) | 672.63 | 752.29 | 802.55 | 911.04 | 1,036.95 | ||||||||||||||
DPS (IDR) | 72.56 | 75.46 | 77.98 | 102.56 | 125.66 | ||||||||||||||
Activity (days) | |||||||||||||||||||
Days receivable | 74.4 | 68.2 | 66.5 | 62.9 | 61.5 | ||||||||||||||
Days inventory | 58.9 | 65.9 | 69.6 | 59.5 | 57.1 | ||||||||||||||
Days payable | 28.2 | 28.6 | 27.1 | 24.4 | 23.4 | ||||||||||||||
Cash cycle | 105.1 | 105.5 | 109.0 | 98.0 | 95.2 | ||||||||||||||
Source: Company data, Verdhana estimates | |||||||||||||||||||
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
| Rating Remains | Buy |
| Target price Reduced from IDR 4,000 | IDR 3,700 |
| Closing price 7 August 2025 | IDR 2,210 |
| Implied upside | +67.4% |
| Market Cap (USD mn) | 3,034.2 |
| ADT (USD mn) | 1.2 |
M cap (USDmn) | 3,034.2 |
Free float (%) | 15.7 |
3-mth ADT (USDmn) | 1.2 |
(%) | 1M | 3M | 12M |
Absolute (IDR) | 3.3 | -2.2 | -14.7 |
Absolute (USD) | 2.9 | -0.7 | -16.0 |
Rel to Jakarta Stock Exchange Composite Index | -5.5 | -10.6 | -18.7 |
Sandy Ham (sandy.ham@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)
Jody Wijaya (jody.wijaya@verdhana.id)
saya
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Based on our survey of distributors and wholesalers, MYOR's domestic sales may have grown
As mentioned in our previous reports, Indonesia local FMCG companies have
Our analysis of FMCG and retail sales data of companies we track across Indonesia suggests that Sulawesi,
AMRT has consistently outperformed its FMCG peers in terms of sales growth over the past decade
Indonesia is a young nation (110mn population are below 40yrs, based on BPS) as well as social media-savvy (th